Can acyclovir cause a decrease in platelet count (thrombocytopenia)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 25, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Acyclovir Cause Thrombocytopenia?

Yes, acyclovir can cause thrombocytopenia, though this is a rare adverse effect that occurs through multiple mechanisms including immune-mediated platelet destruction and thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS). 1

FDA-Recognized Risk

The FDA drug label explicitly warns that "Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), which has resulted in death, has occurred in immunocompromised patients receiving acyclovir therapy." 1 This represents the most serious form of acyclovir-induced platelet decline and carries significant mortality risk.

Mechanisms of Thrombocytopenia

Acyclovir can decrease platelet counts through two distinct pathways:

  • Drug-induced immune thrombocytopenia (DITP): Acyclovir acts as a catalyst for antibody formation that promotes platelet destruction 2. This mechanism is rare but well-documented in case reports 2, 3, 4.

  • TTP/HUS: This microangiopathic process causes consumptive thrombocytopenia and is specifically mentioned in FDA warnings, particularly in immunocompromised patients 1.

Clinical Presentation and Timeline

Acyclovir-induced thrombocytopenia typically develops within days to weeks of starting therapy:

  • Case reports document platelet decline occurring within days of acyclovir initiation 2, 4
  • One documented case showed severe thrombocytopenia (platelets <40,000/μL) developing during hospitalization after acyclovir was started 3
  • In a patient with SLE, thrombocytopenia developed "within days" of starting therapeutic-dose acyclovir 4

High-Risk Populations

Immunocompromised patients face the highest risk, particularly for TTP/HUS 1. Specific high-risk groups include:

  • HIV/AIDS patients on highly active antiretroviral therapy 3
  • Patients with systemic lupus erythematosus (SLE), who require particularly close monitoring with regular platelet counts while on acyclovir 4
  • Any immunocompromised state increases risk of the fatal TTP/HUS complication 1

Dose and Route Considerations

High-dose intravenous acyclovir carries greater risk than oral therapeutic doses:

  • Severe adverse reactions are "mostly related to high dose intravenous administrations" 2
  • Oral acyclovir at standard therapeutic doses rarely causes side effects, with thrombocytopenia being "unusual" 2
  • The FDA specifically warns about intravenous administration risks 1

Diagnostic Approach

When thrombocytopenia develops in a patient on acyclovir, establish temporal relationship and exclude other causes:

  • Document the timing between acyclovir initiation and platelet decline 2
  • Rule out sepsis, heparin-induced thrombocytopenia, consumptive coagulopathy, other medication causes, immune thrombocytopenia, and TTP/HUS from other etiologies 5
  • Consider that baseline thrombocytopenia (<150,000/μL) increases risk of severe on-treatment thrombocytopenia (<50,000/μL) in patients with chronic hepatitis C on antiviral therapy 6

Management

Immediate discontinuation of acyclovir is the primary intervention:

  • Prompt discontinuation results in reversal of thrombocytopenia with good prognosis 2
  • In severe cases (such as the SLE patient), intravenous immunoglobulin may be required in addition to drug discontinuation 4
  • Platelet counts typically recover after acyclovir cessation, as documented in multiple case reports 2, 3, 4

Monitoring Recommendations

For high-risk patients (immunocompromised, SLE, baseline low platelets), implement regular platelet monitoring:

  • Check baseline platelet count before initiating acyclovir 4
  • Monitor platelet counts regularly during treatment, especially in the first 2 weeks 4
  • A high index of suspicion should be maintained in SLE patients requiring acyclovir 4

Clinical Pitfall

Do not confuse acyclovir as a cause versus treatment of thrombocytopenia. One case report documented HSV-2 infection itself causing thrombocytopenia that improved with acyclovir treatment 5. However, this represents viral-induced thrombocytopenia responding to appropriate antiviral therapy, not drug-induced thrombocytopenia. The key distinction is temporal relationship and exclusion of other causes 2, 5.

References

3
Research

A rare case of acyclovir-induced thrombocytopenia.

American journal of therapeutics, 2014

Related Questions

Does acyclovir cause thrombocytopenia?
Is valacyclovir (valacyclovir) safe for a patient with severe thrombocytopenia and a history of cardiovascular disease or high cholesterol?
Is it safe to initiate acyclovir (antiviral medication) in a patient with thrombocytopenia (low platelet count)?
What is the cause of new-onset anemia in a neonate with systemic Herpes Simplex Virus (HSV) infection being treated with acyclovir (acyclovir)?
In a 47‑year‑old woman with systemic lupus erythematosus, past infectious mononucleosis, and ADHD who has persistent intra‑labial lesions despite valacyclovir and a newly enlarged cervical lymph node, what is the most likely diagnosis and recommended management?
In a patient taking aspirin for primary prevention who presents with an acute gastrointestinal bleed, is platelet transfusion indicated?
How is a percutaneous trans‑hepatic biliary drain (PTBD) internalized once the patient is clinically stable, the biliary obstruction is decompressed, there is no ongoing infection, and the tract has matured (approximately 7‑10 days)?
Is nitrofurantoin safe for a 71‑year‑old patient with an estimated glomerular filtration rate of 61 mL/min?
Is abdominal ultrasound (USG) appropriate as a first‑line imaging study for a patient with a distended abdomen?
What antibiotics are appropriate for a patient with an ear infection?
For a patient with type 1 or type 2 diabetes needing basal insulin, should I start Tresiba (insulin degludec) or insulin glargine, considering dosing flexibility, nocturnal hypoglycemia risk, and cost?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question